This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2010 Jun;34(6):698-9.

doi: 10.1016/j.leukres.2009.12.009. Epub 2010 Jan 13.

Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia

N Widmer, V Gotta, A Haouala, L A Decosterd

PMID: 20074797
DOI: 10.1016/j.leukres.2009.12.009

Editorial

Tyrosine kinase inhibitors concentration monitoring in chronic myeloid leukemia

N Widmer et al. Leuk Res. 2010 Jun.

. 2010 Jun;34(6):698-9.

doi: 10.1016/j.leukres.2009.12.009. Epub 2010 Jan 13.

Authors

N Widmer, V Gotta, A Haouala, L A Decosterd

PMID: 20074797
DOI: 10.1016/j.leukres.2009.12.009

No abstract available

PubMed Disclaimer

Comment on

Facts and uncertainties in monitoring treatment response in chronic myeloid leukaemia.
Clark RE. Clark RE. Leuk Res. 2009 Sep;33(9):1151-5. doi: 10.1016/j.leukres.2009.04.001. Epub 2009 May 15. Leuk Res. 2009. PMID: 19446877
Are there new clinical parameters useful to predict response in chronic myeloid leukemia in the imatinib era?
Breccia M, Alimena G. Breccia M, et al. Leuk Res. 2009 Nov;33(11):1450-1. doi: 10.1016/j.leukres.2009.06.022. Epub 2009 Jul 16. Leuk Res. 2009. PMID: 19615745 No abstract available.

Similar articles

Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia.
Khan KA, Junaid A, Siddiqui NS, Mukhtar K, Siddiqui S. Khan KA, et al. J Coll Physicians Surg Pak. 2008 Mar;18(3):176-8. J Coll Physicians Surg Pak. 2008. PMID: 18460249
Renal failure associated with tyrosine kinase inhibitors--case report and review of the literature.
Gafter-Gvili A, Ram R, Gafter U, Shpilberg O, Raanani P. Gafter-Gvili A, et al. Leuk Res. 2010 Jan;34(1):123-7. doi: 10.1016/j.leukres.2009.07.009. Epub 2009 Jul 28. Leuk Res. 2010. PMID: 19640584 Review.
New tyrosine kinase inhibitors in chronic myeloid leukemia.
Martinelli G, Soverini S, Rosti G, Cilloni D, Baccarani M. Martinelli G, et al. Haematologica. 2005 Apr;90(4):534-41. Haematologica. 2005. PMID: 15820950
Partial fanconi syndrome induced by imatinib therapy: a novel cause of urinary phosphate loss.
François H, Coppo P, Hayman JP, Fouqueray B, Mougenot B, Ronco P. François H, et al. Am J Kidney Dis. 2008 Feb;51(2):298-301. doi: 10.1053/j.ajkd.2007.10.039. Am J Kidney Dis. 2008. PMID: 18215707
Practical management of patients with chronic myeloid leukemia receiving imatinib.
Deininger MW, O'Brien SG, Ford JM, Druker BJ. Deininger MW, et al. J Clin Oncol. 2003 Apr 15;21(8):1637-47. doi: 10.1200/JCO.2003.11.143. Epub 2003 Mar 13. J Clin Oncol. 2003. PMID: 12668652 Review.

See all similar articles

Cited by

Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels.
Gotta V, Widmer N, Montemurro M, Leyvraz S, Haouala A, Decosterd LA, Csajka C, Buclin T. Gotta V, et al. Clin Pharmacokinet. 2012 Mar 1;51(3):187-201. doi: 10.2165/11596990-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22339450

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information